David A. Lipson, M.D.

Adjunct Associate Professor of Medicine
Director, Clinical Drug Discovery
Respiratory Discovery Medicine
GlaxoSmithKline

GlaxoSmithKline
709 Swedeland Road, UW2531
King of Prussia, PA 19406
email:  david.a.lipson@gsk.com

Office: (610) 270-7166
FAX: (610) 270-5360

Education:

MD: Thomas Jefferson University

Residency: Hospital of the University of Pennsylvania

Fellowship: Hospital of the University of Pennsylvania

Dr. Lipson is currently an Adjunct Associate Professor of Medicine in the Pulmonary, Allergy, and Critical Care Division and serves as Director, Clinical Drug Discovery at GlaxoSmithKline. Before joining industry in 2007, Dr. Lipson served as the Director of the Obstructive Lung Disease Program and the Adult Cystic Fibrosis Program at Penn. While under his direction, the Adult Cystic Fibrosis Program received a JCAHO Best Practice Nomination and was named Best Comprehensive Adult Cystic Fibrosis Program in Philadelphia Magazine. His clinical interests include Chronic Obstructive Pulmonary Disease, adult cystic fibrosis, and bronchiectasis. He served as an attending physician on the Advanced Lung Disease and Lung Transplantation Service, as well as in the Medical Intensive Care Unit at the Hospital of the University of Pennsylvania. He currently is an attending physician in the Pulmonary Fellow’s Outpatient Practice. Dr. Lipson was formerly the Associate Director of the Pulmonary and Critical Care Fellowship Training Program at Penn.

Dr. Lipson performs clinical research in drug development for respiratory diseases including COPD, cystic fibrosis, and acute lung injury. Formerly, he was awarded a NIH K23 grant to determine clinical risk factors for the development of obliterative bronchiolitis (OB -- chronic lung rejection) following lung transplantation. Additionally, he studied the use of hyperpolarized helium-3 MRI in the early detection of OB. Dr. Lipson is interested in novel, non-invasive radiologic imaging techniques in order to study ventilation and perfusion relationships in the lung.

Dr. Lipson was a principal investigator or co-investigator on numerous clinical trials including the NIH-sponsored multi-center study of Lung Volume Reduction Surgery for emphysema (National Emphysema Treatment Trial -- NETT).

Dr. Lipson completed his undergraduate work at the University of Pennsylvania where he graduated cum laude and with Distinction in the Major. He then obtained his MD degree at Jefferson Medical College. At Jefferson, he was awarded the W.W. Smith Scholarship for academic achievement and was elected to the Hobart Amory Hare Medical Honor Society. Dr. Lipson subsequently returned to Penn for his internship and residency in Internal Medicine. Following his residency, Dr. Lipson completed his Pulmonary and Critical Care training at Penn where he received the 2000-2001 Will Rogers Institute Fellowship Award. The American Board of Internal Medicine (ABIM) boarded him in Internal Medicine, Pulmonary Disease, and Critical Care. From 2003-2007 he served as physician-secretary of the Pulmonary Disease Board of the ABIM.

Books:

Lipson DA, van Beek EJR. Eds. Functional Lung Imaging. Taylor Francis, Inc. Publisher. New York, New York. (2005)

Representative Recent Publications:

Lipson DA, Lomas DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer, R. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in COPD patients. Accepted Journal of Clinical Pharmacology (2011).

Misurski DA, Lipson DA, Changolkar AK. Cost of Inappropriate Empiric Antibiotic Prescribing in Subjects with Influenza in a Commercially Insured United States Population. Accepted American Journal of Managed Care (2011).

Chandra, D, Lipson, DA, Hoffman EA, Hansen-Flaschen J, Sciurba FC, DeCamp, MM, Reilly JJ, Washko GR. Perfusion scintigraphy and patient selection for lung volume reduction surgery. Am J Resp Crit Care Med 182:937-946 (2010).

Sharafkhaneh A, Falk JA, Minai OA, Lipson DA. Overview of the Perioperative Management of Lung Volume Reduction Surgery Patients. Proc Am Thorac Soc 5:438-441. (2008).

DeCamp M, Lipson D, Krasna M, Minai O, McKenna R, Thomashow BM. The Evaluation and Preparation of the Patient for Lung Volume Reduction Surgery. Proc Am Thorac Soc 5:427-431 (2008).

Lipson DA, Weinberger S. Approach to the patient with disease of the respiratory system. In: Harrison's Principles of Internal Medicine, 17th Edition. Dennis L. Kasper, Eugene Braunwald, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, and Kurt J. Isselbacher, Eds. McGraw-Hill Publishers (2008).

Weinberger S, Lipson DA. Cough and hemoptysis. In: Harrison's Principles of Internal Medicine, 17th Edition. Dennis L. Kasper, Eugene Braunwald, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, and Kurt J. Isselbacher, Eds. McGraw-Hill Publishers (2008).

Ishii M, Emami K, Kadlecek S, Petersson JS, Golman K, Vahdat V, Yu J, Cadman RV, MacDuffie-Woodburn JM, Stephen M, Lipson D, Rizi R. Hyperpolarized 13C MRI of the Pulmonary Vasculature and Parenchyma. Magn Res Med 57(3):459-463 (2007).

Yu J, Ishii M, Kadlecek S, Lipson DA, Emami K, Clark TW, Rajaei S, Rizi RR. Multiple Regression Method for Pulmonary Apparent Diffusion Coefficient Measurement by Hyperpolarized 3He MRI.  J Magn Reson Imaging. 25(5):982-991 (2007).

Belkin R, Henig N, Singer L, Rubenstein R, Xie S, Kotloff RM, Lipson DA, Bunin, GR. Risk Factors for Death of Patients with Cystic Fibrosis Awaiting Lung Transplantation. Am J Respir Crit Care Med 173:659–666 (2006).

Lipson DA. Tiotropium Bromide. International Journal of COPD. 1(2): 107-114 (2006).
Machuzak MS and Lipson DA. Surgical Options in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine. 13(1):1-7 (2006).

Ishii M, Fischer MC, Emami K, Alavi A, Spector ZZ, Yu J, Baumgardner JE, Itkin M, Kadlecek SJ, Zhu J, Bono M, Gefter WB, Lipson DA, Shrager JB, Rizi RR. Hyperpolarized Helium-3 MR Imaging of Pulmonary Function.  In: Pet Imaging II. A Alavi (Ed.) Radiologic Clinics of North America 43:235-246 (2005).

Lipson DA and Sager JS. Noninvasive Ventilation. New England Journal of Medicine. 351:1257-1259 (2004).

Lipson DA. Redefining Treatment in COPD: New Directions in Bronchodilator Therapy. Treatments in Respiratory Medicine. 3(2):89-95. (2004).

National Emphysema Treatment Trial Research Group. A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe Emphysema. New England Journal of Medicine, 348:2059-2073. (2003).

Lipson DA, Roberts DA, Hansen-Flaschen J, Gentile TR, Jones G, Thompson A, Dimitrov IE, Palevsky HI, Leigh JS, Schnall M, and Rizi RR. Pulmonary Ventilation and Perfusion Scanning Using Hyperpolarized Helium-3 MRI and Arterial Spin Tagging in Healthy Normal Subjects, and in Pulmonary Embolism, and Orthotopic Lung Transplant Patients. Magnetic Resonance in Medicine, 47:1073-1076 (2002).

Lipson DA, Edelman JD, Palevsky HI. Alternatives to Lung Transplantation: Lung Volume Reduction Surgery and Continuous Intravenous Prostacyclin. Transplant Proc, 34(4):1283-1286. (2002).

Kotloff RM, Hansen-Flaschen J, Lipson DA, Tino G, Arcasoy SM, Kaiser LR, and Alavi A. Apical Perfusion Fraction as a Predictor of Short Term Functional Outcome Following Bilateral Lung Volume Reduction Surgery. Chest, 120(5):1609-1615 (2001).

Lipson DA, Palevsky HI, Kotloff RM, and Edelman J. Conversion to Tacrolimus (FK 506) from Cyclosporine After Orthotopic Lung Transplantation.Transplant Proc, 30(4):1505-1507 (1998).